News
NGNE
45.95
+7.91%
3.37
Weekly Report: what happened at NGNE last week (0708-0712)?
Weekly Report · 8h ago
Weekly Report: what happened at NGNE last week (0701-0705)?
Weekly Report · 07/08 12:10
Neurogene to Participate in BMO Genetic Medicines Summit
Neurogene management will participate in the BMO 2024 Genetic Medicines Summit. The company's mission is to bring life-changing genetic medicines to patients and families affected by rare neurological diseases. Neurogene is developing novel approaches to address the limitations of conventional gene therapy in central nervous system disorders.
Barchart · 07/02 06:30
Weekly Report: what happened at NGNE last week (0624-0628)?
Weekly Report · 07/01 12:11
Neurogene to join Russell 3000 Index
Seeking Alpha · 07/01 11:45
Neurogene Announces Addition to Russell 3000® Index
Neurogene will be added to the Russell 3000 Index effective July 1, 2024. The Russell indexes capture the 4,000 largest U.S. Stocks by total market capitalization. Neurogene is a clinical-stage company developing genetic medicines to treat rare neurological diseases. The company is developing a gene therapy for Rett syndrome.
Barchart · 07/01 06:30
NEUROGENE INC <NGNE.O>: BMO INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $65
Reuters · 06/27 10:44
Neurogene Initiated at Outperform by BMO Capital
Dow Jones · 06/27 09:27
Neurogene Price Target Announced at $65.00/Share by BMO Capital
Dow Jones · 06/27 09:27
BMO Capital Initiates Coverage On Neurogene with Outperform Rating, Announces Price Target of $65
Benzinga · 06/27 09:17
U.S. RESEARCH ROUNDUP-Carnival, FedEx, Micron Technology
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Carnival, FedEx and Micron Technology among those with revised targets. FedEx raises target price to $318 from $296; AIG cuts target price. Acadia Pharmaceuticals, Exact Sciences and other companies also see analyst downgrades.
Reuters · 06/27 07:55
Weekly Report: what happened at NGNE last week (0617-0621)?
Weekly Report · 06/24 12:21
Neurogene Buy Rating Affirmed Amid Competitor’s Setback and Promising NGN-401 Prospects
TipRanks · 06/24 06:05
Neurogene Releases Updated Corporate Presentation Online
TipRanks · 06/21 12:58
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Tempest Therapeutics (NASDAQ:TPST) shares rose 32.8% to $3.79 during Thursday's pre-market session. Neurogene shares rose 31.92% during the session. Geovax Labs and SAB Biotherapeutics also rose. Mustang Bio stock fell 27.4% in the same session.
Benzinga · 06/20 12:05
TD Cowen Keeps Their Buy Rating on Neurogene (NGNE)
TipRanks · 06/20 11:25
Buy Rating Maintained for Neurogene Amid Promising Efficacy of NGN-401 Treatment
TipRanks · 06/20 10:37
Neurogene’s Undervalued Stock: A Strong Buy Amidst Market Overreaction to Competitors’ Trial Results
TipRanks · 06/20 07:55
Neurogene’s Rett Syndrome Trial Shows Promise
TipRanks · 06/19 23:38
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Quantum Corporation shares dipped 44.5% to $0.43 on Tuesday. The company reported worse-than-expected FY24 financial results and issued FY25 guidance below estimates. Reliance Global Group, Inc. Shares jumped 350% in today's mid-day session. NLS Pharmaceutics AG shares rose 166% on Monday.
Benzinga · 06/18 17:39
More
Webull provides a variety of real-time NGNE stock news. You can receive the latest news about Neurogene through multiple platforms. This information may help you make smarter investment decisions.
About NGNE
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in pediatric female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.